[
  {
    "ts": null,
    "headline": "Thermo Fisher Scientific Declares Quarterly Dividend",
    "summary": "WALTHAM, Mass., July 10, 2025--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.43 per common share, payable on October 15, 2025, to shareholders of record as of September 15, 2025.",
    "url": "https://finnhub.io/api/news?id=6a15fc030451c1ffe881868ddd68899afb54e1fd47f2b91a2e6d05fe9699586a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752178500,
      "headline": "Thermo Fisher Scientific Declares Quarterly Dividend",
      "id": 135863787,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "WALTHAM, Mass., July 10, 2025--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.43 per common share, payable on October 15, 2025, to shareholders of record as of September 15, 2025.",
      "url": "https://finnhub.io/api/news?id=6a15fc030451c1ffe881868ddd68899afb54e1fd47f2b91a2e6d05fe9699586a"
    }
  },
  {
    "ts": null,
    "headline": "Delaware Supreme Court sides with Zantac drugmakers over cancer evidence",
    "summary": "Delaware's highest court ruled onThursday that nearly 75,000 patients suing four large drugmakerscannot introduce reports from several experts to support theirclaim that the heartburn drug Zantac...",
    "url": "https://finnhub.io/api/news?id=7ff90bc29ae42f7f5a7bdc3849eb401cffadca95f45420b40849e5ff6832ed1d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752165491,
      "headline": "Delaware Supreme Court sides with Zantac drugmakers over cancer evidence",
      "id": 135863011,
      "image": "",
      "related": "TMO",
      "source": "Finnhub",
      "summary": "Delaware's highest court ruled onThursday that nearly 75,000 patients suing four large drugmakerscannot introduce reports from several experts to support theirclaim that the heartburn drug Zantac...",
      "url": "https://finnhub.io/api/news?id=7ff90bc29ae42f7f5a7bdc3849eb401cffadca95f45420b40849e5ff6832ed1d"
    }
  },
  {
    "ts": null,
    "headline": "Thermo Fisher Scientific Inc. stock rises Thursday, outperforms market",
    "summary": "Thermo Fisher Scientific Inc. stock rises Thursday, outperforms market",
    "url": "https://finnhub.io/api/news?id=9de4e9212110b812365253c751af49f26e000f26ff479c9b9dd2593027c8ee97",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752165300,
      "headline": "Thermo Fisher Scientific Inc. stock rises Thursday, outperforms market",
      "id": 135950506,
      "image": "",
      "related": "TMO",
      "source": "MarketWatch",
      "summary": "Thermo Fisher Scientific Inc. stock rises Thursday, outperforms market",
      "url": "https://finnhub.io/api/news?id=9de4e9212110b812365253c751af49f26e000f26ff479c9b9dd2593027c8ee97"
    }
  },
  {
    "ts": null,
    "headline": "ClearBridge Appreciation Strategy Q2 2025 Commentary",
    "summary": "The ClearBridge Appreciation Strategy underperformed the benchmark S&P 500 Index in the second quarter. On an absolute basis, the Strategy had gains in seven of 11 sectors.",
    "url": "https://finnhub.io/api/news?id=36b49fe24baf46d3641aa0635fc34d4f91dea6a18c599a0c0333ca041eeee170",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752163620,
      "headline": "ClearBridge Appreciation Strategy Q2 2025 Commentary",
      "id": 135862073,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1645710848/image_1645710848.jpg?io=getty-c-w1536",
      "related": "TMO",
      "source": "SeekingAlpha",
      "summary": "The ClearBridge Appreciation Strategy underperformed the benchmark S&P 500 Index in the second quarter. On an absolute basis, the Strategy had gains in seven of 11 sectors.",
      "url": "https://finnhub.io/api/news?id=36b49fe24baf46d3641aa0635fc34d4f91dea6a18c599a0c0333ca041eeee170"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights SAP SE, Novo Nordisk, Thermo Fisher Scientific and FONAR",
    "summary": "SAP, NVO, TMO and FONR navigate growth and headwinds as analysts spotlight cloud momentum, obesity drugs, and innovation plays.",
    "url": "https://finnhub.io/api/news?id=5684386d265d6eafeeb60e51b3d4e5ab566219513ff28b36298b8afd6250fa7c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752140100,
      "headline": "The Zacks Analyst Blog Highlights SAP SE, Novo Nordisk, Thermo Fisher Scientific and FONAR",
      "id": 135850219,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "SAP, NVO, TMO and FONR navigate growth and headwinds as analysts spotlight cloud momentum, obesity drugs, and innovation plays.",
      "url": "https://finnhub.io/api/news?id=5684386d265d6eafeeb60e51b3d4e5ab566219513ff28b36298b8afd6250fa7c"
    }
  }
]